Climb Bio (NASDAQ:CLYM) Reaches New 12-Month High Following Analyst Upgrade

Climb Bio, Inc. (NASDAQ:CLYM) hit a new 52-week high during trading on Tuesday after HC Wainwright raised their price target on the stock from $15.00 to $20.00. HC Wainwright currently has a buy rating on the stock. Climb Bio traded as high as $12.48 and last traded at $11.12, with a volume of 1248701 shares traded. The stock had previously closed at $11.37.

A number of other research analysts have also recently commented on CLYM. Robert W. Baird set a $21.00 price target on Climb Bio in a research report on Wednesday, May 6th. Wedbush lifted their target price on Climb Bio from $15.00 to $17.00 and gave the company an “outperform” rating in a research report on Friday, May 8th. Chardan Capital started coverage on Climb Bio in a research report on Tuesday, May 5th. They issued a “buy” rating and a $22.00 target price on the stock. Truist Financial started coverage on Climb Bio in a research report on Tuesday, March 17th. They issued a “buy” rating and a $17.00 target price on the stock. Finally, Piper Sandler started coverage on Climb Bio in a research report on Friday, February 13th. They issued an “overweight” rating on the stock. Three research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $20.30.

Climb Bio News Summary

Here are the key news stories impacting Climb Bio this week:

• Positive Sentiment: Climb Bio announced it will present new budoprutug clinical data at the European Hematology Association (EHA) 2026 Congress in June, which could highlight progress in its lead program and support sentiment around the biotech pipeline. Climb Bio to Present New Budoprutug Clinical Data at European Hematology Association (EHA) 2026 Congress
• Positive Sentiment: HC Wainwright reiterated a Buy rating and raised its price target on Climb Bio to $20, signaling continued analyst confidence in the stock’s upside. Climb Bio (NASDAQ:CLYM) Given New $20.00 Price Target at HC Wainwright
• Positive Sentiment: HC Wainwright lifted earnings estimates for FY2026, FY2027 and several quarterly periods, suggesting a modestly improving outlook for losses as the company advances its clinical development.
• Neutral Sentiment: The company remains unprofitable, with analyst estimates still calling for losses through 2027, so the near-term story remains focused on pipeline execution rather than earnings power.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of CLYM. AQR Capital Management LLC acquired a new stake in shares of Climb Bio during the first quarter valued at about $27,000. Goldman Sachs Group Inc. acquired a new stake in shares of Climb Bio during the first quarter valued at about $147,000. Marshall Wace LLP acquired a new stake in shares of Climb Bio during the second quarter valued at about $46,000. Qube Research & Technologies Ltd acquired a new stake in shares of Climb Bio during the second quarter valued at about $43,000. Finally, Jane Street Group LLC acquired a new stake in shares of Climb Bio during the second quarter valued at about $184,000. Institutional investors own 69.76% of the company’s stock.

Climb Bio Stock Up 2.1%

The stock has a 50 day moving average price of $8.23 and a 200 day moving average price of $5.33. The stock has a market capitalization of $653.34 million, a price-to-earnings ratio of -14.63 and a beta of 0.02.

Climb Bio (NASDAQ:CLYM) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($0.20) EPS for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.06. Sell-side analysts forecast that Climb Bio, Inc. will post -0.92 earnings per share for the current fiscal year.

About Climb Bio

Climb Bio Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered protein therapeutics for the treatment of cancer and immune-mediated disorders. The company’s mission centers on designing biologics with enhanced specificity and functional activity to engage key cellular targets and improve patient outcomes in areas of high unmet need.

At the heart of Climb Bio’s approach is its proprietary protein engineering platform, which combines mammalian cell display, directed evolution and computational modeling.